CBIO NASDAQ
Crescent Biopharma, Inc.
1W: +3.2%
1M: -8.8%
3M: -22.4%
YTD: +15.2%
1Y: -0.2%
3Y: -90.2%
5Y: -93.4%
$13.27
+0.51 (+4.00%)
After Hours: $13.45 (+0.18, +1.39%)
Weekly Expected Move ±9.0%
$11
$12
$13
$14
$15
Credit Risk of going bust: lower than 71% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Crescent Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.4M against a stock market value of $474.0M.
Distance to default 7.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $718K (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' 4.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Crescent Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.4M against a stock market value of $474.0M.
Distance to default 7.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $718K (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' 4.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$12.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$474.0M
52W Range8.72-27.41
Volume210,636
Avg Volume386,874
Beta1.26
Dividend—
Analyst Ratings
Company Info
CEOJoshua T. Brumm
Employees44
SectorHealthcare
IndustryBiotechnology
IPO Date2014-01-10
Websitecrescentbiopharma.com
300 Fifth Avenue
Waltham, MA 02451
US
Waltham, MA 02451
US
617-430-5595
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Latest News
Crescent Biopharma, Inc. (NASDAQ:CBIO) Stock Has Average Price Target of $32.40 According to Analysts
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,098.00 in Stock
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CEO Sells $28,819.00 in Stock
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,151.70 in Stock
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CFO Sells $10,167.20 in Stock
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Brumm Joshua T | S-Sale | 7,837 | $16.71 | 2026-09-18 |
| McNeill Jonathan | S-Sale | 3,839 | $16.71 | 2026-09-18 |
| Lynch Ryan | S-Sale | 240 | $17.90 | 2026-09-16 |
| Pinkas Jan | S-Sale | 658 | $17.90 | 2026-09-16 |
| Im Ellie Eunkyung | S-Sale | 623 | $17.90 | 2026-09-16 |